Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sensory System Agents Clear all
Recruiting Phase 1Phase 2 Interventional

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139
View directory record Official record
Conditions
Breast Cancer, Solid Tumors, Adult
Interventions
STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 9, 2026, 1:55 AM EDT
Terminated Phase 1 Interventional

Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM

NCT04489420
View directory record Official record
Conditions
Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme, Cyclophosphamide, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Molecular Mechanisms of Pharmacological Action, Antiviral Agents, Anti-infective Agents, Analgesics, Non-narcotic, Analgesics, Sensory System Agents, Peripheral Nervous System Agents
Interventions
CYNK001-IV, CYNK001-IT
Biological
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Sep 9, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

NCT04564027
View directory record Official record
Conditions
Advanced Solid Tumours
Interventions
Ceralasertib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
12
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 9, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

Stellate Ganglion Block for COVID-induced Parosmia

NCT06253806
View directory record Official record
Conditions
COVID-19-Induced Parosmia
Interventions
Stellate Ganglion Block, Placebo Sham Injection
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 9, 2026, 1:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans

NCT04032301
View directory record Official record
Conditions
Post-Traumatic Stress Disorders, Major Depressive Disorder
Interventions
Ketamine, Normal Saline
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 9, 2026, 1:55 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Repeated Neurocognitive Measurements in Depressed Patients

NCT05991232
View directory record Official record
Conditions
Depression, Unipolar
Interventions
Intravenous Ketamine
Drug
Lead sponsor
Jay Fournier
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 9, 2026, 1:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]

NCT04178993
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Methamphetamine, Methylphenidate, Placebo oral capsule, Duloxetine
Drug
Lead sponsor
Craig Rush
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 8, 2023 · Synced Sep 9, 2026, 1:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ketamine Infusions for PTSD and Treatment-Resistant Depression

NCT02577250
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant, Stress Disorders, Post-Traumatic
Interventions
Ketamine
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Sep 9, 2026, 1:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Medications Development for the Treatment of Cannabis Related Disorders

NCT01204723
View directory record Official record
Conditions
Nicotine Withdrawal, Marijuana Dependence, Cannabis Dependence, Nicotine Dependence, Cannabis Abuse
Interventions
Placebo Aprepitant, Active Aprepitant
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 45 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
2
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Sep 9, 2026, 1:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers

NCT02045264
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
Icatibant (30 mg)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 9, 2026, 1:55 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Plasma Glucose Levels With Dexamethasone as Adjuvant to Interscalene Block

NCT01538459
View directory record Official record
Conditions
Shoulder Pain, Injury of Shoulder Region, Disorder of Shoulder, Disorder of Rotator Cuff, Disorder of Tendon of Biceps
Interventions
Dexamethasone, Bupivacaine
Drug
Lead sponsor
Lifespan
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Newport, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 19, 2013 · Synced Sep 9, 2026, 1:55 AM EDT
Completed Phase 4 Interventional Results available

Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users

NCT02445339
View directory record Official record
Conditions
Alcohol Dependence, Alcohol Use Disorder
Interventions
XR-NTX+CM (Extended-Release Naltrexone plus Care Management)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Sep 9, 2026, 1:55 AM EDT
Recruiting Phase 1 Interventional

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

NCT07064122
View directory record Official record
Conditions
Haematologic Neoplasms
Interventions
AZD2962
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 110 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 9, 2026, 1:55 AM EDT
Recruiting Phase 1Phase 2 Interventional

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

NCT07558733
View directory record Official record
Conditions
HR+ HER2- Breast Cancer
Interventions
Serabelisib, Sapanisertib, Fulvestrant
Drug
Lead sponsor
Faeth Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
7
States / cities
Los Angeles, California • Lone Tree, Colorado • Springfield, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 9, 2026, 1:55 AM EDT
Recruiting Phase 3 Interventional

Nebulized Ketamine for the Treatment of Major Depressive Disorder

NCT06752759
View directory record Official record
Conditions
Severe Depression, Moderate Depression, Ketamine, Midazolam, Peripheral Nervous System Agents, Central Nervous System Agents, Neurotransmitter Agents, Physiologic Effects of Drugs, Sensory System Agents, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal, Depressive Symptom, Hypnotics and Sedatives, Anti-anxiety Agents, Tranquilizing Agents, Psychotropic Drugs, Anesthetics Agent
Interventions
nebulized ketamine, nebulized midazolam
Drug
Lead sponsor
Theresa Jacob, PhD, MPH
Other
Eligibility
18 Years to 88 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 9, 2026, 1:55 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

NCT06993844
View directory record Official record
Conditions
Advanced Solid Tumors, Advanced Breast Cancer
Interventions
ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant, ETX-636 dose expansion in combination with fulvestrant
Drug
Lead sponsor
Ensem Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Newport Beach, California • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 9, 2026, 1:55 AM EDT
Completed Phase 4 Interventional

Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression

NCT05615948
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Analgesia, Ketamine, Peripheral Nervous System Agents, Central Nervous System Depressants, Neurotransmitter Agents, Anti-Inflammatory Agents, Physiological Effects of Drugs, Sensory System Agents, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal, Depressive Symptoms
Interventions
VTS-K
Drug
Lead sponsor
Theresa Jacob, PhD, MPH
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 9, 2026, 1:55 AM EDT
Completed Not applicable Interventional Results available

Pregabalin for the Treatment of Pain After Posterior Spinal Fusions

NCT01366196
View directory record Official record
Conditions
Lumbar Spinal Fusions
Interventions
Pregabalin 150 mg, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
21 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 9, 2026, 1:55 AM EDT
Not listed Phase 1 Interventional

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

NCT04309084
View directory record Official record
Conditions
Multiple Myeloma, Neoplasm, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorder, Vascular Diseases, Cardiovascular Diseases, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Diseases, Antineoplastic Agents, Analgesics, Non-Narcotic, Analgesics, Sensory System Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs
Interventions
CYNK-001
Biological
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Denver, Colorado • St Louis, Missouri • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 9, 2026, 1:55 AM EDT
Recruiting No phase listed Observational

Natural History of Depression, Bipolar Disorder and Suicide Risk

NCT06462196
View directory record Official record
Conditions
Behavioral Symptoms, Suicide, Self-Injurious Behavior, Sensory System Agents, Analgesics, Peripheral Nervous System Agents, Physiological Effects of Drugs, Anesthetics, Dissociative, Anesthetics, General, Anesthetics, Central Nervous System Depressants, Excitatory Amino Acid Antagonists, Excitatory Amino Acid Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Ketamine, Depression, Unipolar, Depressive Symptoms, Treatment Resistant Depression, Major Depressive Disorder, Depression, Bipolar
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 120 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 9, 2026, 1:55 AM EDT
Recruiting Phase 2 Interventional

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

NCT06463028
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Sapanisertib, Serabelisib, Paclitaxel
Drug
Lead sponsor
Faeth Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
18
States / cities
La Jolla, California • San Francisco, California • Miami Beach, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 9, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.

NCT02634684
View directory record Official record
Conditions
Schizophrenia
Interventions
Dextroamphetamine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Sep 9, 2026, 1:55 AM EDT